Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Mainz Biomed B.V. MYNZ NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Diagnostics & Research • DE • USD

SharesGrow Score
26/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Mainz Biomed B.V. (MYNZ) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $0.70. It has a SharesGrow Score of 25/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Financials: revenue is $537,080, +9.6%/yr average growth. Net income is $16M (loss), growing at +14.5%/yr. Net profit margin is -3018.3% (negative). Gross margin is 72.6% (+38.2 pp trend).

Balance sheet: total debt is $2M against $641,600 equity (Debt-to-Equity (D/E) ratio 3.72, leveraged). Current ratio is 0.5 (tight liquidity). Debt-to-assets is 44.8%. Total assets: $5M.

Analyst outlook: 1 / 3 analysts rate MYNZ as buy (33%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 73/100 (Pass), Past 0/100 (Fail), Health 0/100 (Fail), Moat 50/100 (Partial), Future 20/100 (Fail), Income 10/100 (Fail).

MYNZ SharesGrow Score Overview

38/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 73/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 0/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 20/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MYNZ

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
73/100
MYNZ: +9.6%/yr revenue is, +14.5%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
—
HEALTH N/A
N/A
No analyst coverage available for this stock.
~
MOAT Partial
50/100
MYNZ: Gross margin is 72.6% (+38.2 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
20/100
Analyst outlook: 1 / 3 analysts rate MYNZ as buy (33%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
MYNZ: Net profit margin is -3018.3%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.5476-5.34
Volume21.83K
Avg Volume (30D)554.37K
Market Cap$2.86M
Beta (1Y)0.32
Share Statistics
EPS (TTM)-2.70
Shares Outstanding$6M
IPO Date2021-11-05
Employees19
CEOGuido Baechler
Financial Highlights & Ratios
Revenue (TTM)$537.08K
Gross Profit$389.79K
EBITDA$-16.14M
Net Income$-16.21M
Operating Income$-16.14M
Total Cash$889.09K
Total Debt$2.39M
Net Debt$1.5M
Total Assets$5.33M
Price / Earnings (P/E)-0.3
Price / Sales (P/S)5.33
Analyst Forecast
Rating ConsensusHold
Analysts Covering3
Buy 33% Hold 67% Sell 0%
Company Info
CountryDE
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINNL0015000LC2

Price Chart

Track all markets on TradingView
MYNZ
Mainz Biomed B.V. ↗  ·  NASDAQ Capital Marke
Healthcare • Medical - Diagnostics & Research
0.55 52WK RANGE 5.34

People Also View

OLK
OLK
Olink Holding AB (publ)
$26.08
+0.31%
 LAB
LAB
Standard BioTools Inc.
$0.98
+10.45%
 PRE
PRE
Prenetics Global Limited
$17.75
-1.44%
 GTH
GTH
Genetron Holdings Limited
$4.03
+0.12%
 MDXH
MDXH
MDxHealth S.A.
$2.31
+1.76%
 FONR
FONR
FONAR Corporation
$18.77
+0.05%
 STIM
STIM
Neuronetics, Inc.
$1.39
-2.80%
 BDSX
BDSX
Biodesix, Inc.
$12.66
+4.28%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message